References
- Coco D, Leanza S. Von Hippel-Lindau Syndrome: Medical Syndrome or Surgical Syndrome? A Surgical Perspective. J Kidney Cancer VHL. 2021 Dec 5;9(1):27-32. doi: 10.15586/jkcvhl.v9i1.206. PMID: 34963877; PMCID: PMC8652351
- Larcher A, Belladelli F, Fallara G, Rowe I, Capitanio U, Marandino L, Raggi D, Capitanio JF, Bailo M, Lattanzio R, Barresi C, Calloni SF, Barbera M, Andreasi V, Guazzarotti G, Pipitone G, Carrera P, Necchi A, Mortini P, Bandello F, Falini A, Partelli S, Falconi M, De Cobelli F, Salonia A. Multidisciplinary management of patients diagnosed with von Hippel-Lindau disease: A practical review of the literature for clinicians. Asian J Urol. 2022 Oct;9(4):430-442. doi: 10.1016/j.ajur.2022.08.002. Epub 2022 Sep 10. PMID: 36381595; PMCID: PMC9643295.)
- Pradhan R, George N, Mandal K, Agarwal A, Gupta SK. Endocrine Manifestations of Von Hippel-Landau Disease. Indian J Endocrinol Metab. 2019 Jan-Feb;23(1):159-164. doi: 10.4103/ijem.IJEM_252_18. PMID: 31016171; PMCID: PMC6446673
- van Leeuwaarde RS, Ahmad S, van Nesselrooij B, et al.Von Hippel-Lindau Syndrome. 2000 May 17 (Updated 2023 Sep 21). In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® (Internet). Seattle (WA): University of Washington, Seattle; 1993-2023
- Karimi S, Arabi A, Shahraki T, Safi S. Von Hippel-Lindau Disease and the Eye. J Ophthalmic Vis Res. 2020 Feb 2;15(1):78-94. doi: 10.18502/jovr.v15i1.5950. PMID: 32095212; PMCID: PMC7001024.
- Hudler P, Urbancic M. The Role of VHL in the Development of von Hippel-Lindau Disease and Erythrocytosis. Genes (Basel). 2022 Feb 17;13(2):362. doi: 10.3390/genes13020362. PMID: 35205407; PMCID: PMC8871608.
- Waldum H. Dysfunction of von-Hippel Lindau factor causes reduced degradation of HIF leading to renal cancer. Hypoxiainducible factor-prolyl hydroxylase enzyme inhibitors also lessen HIF destruction and could therefore increase renal cancer. Front Pharmacol. 2023 Jun 6;14:1170796. doi: 10.3389/fphar.2023.1170796. PMID: 37346300; PMCID: PMC10279847.